Logical and Arsenal Get $10M Apiece, Constant Contact Acquires NutshellMail, Avila Gets $209M From Clovis, & More Boston-Area Deals News
(Page 2 of 2)
testing of NormOxys’ drug for getting oxygen to deprived tissues in patients with chronic heart failure and cancer.
—Waltham, MA-based online marketing software maker Constant Contact (NASDAQ: CTCT) purchased NutshellMail, a Menlo Park, CA-based company that makes software enabling small businesses to monitor social networking sites, for an undisclosed sum. The company’s Bay Area office is expected to open later this year, and will be led by NutshellMail’s co-founders.
—Swaptree, a Cambridge, MA-based website for trading used books, DVDs, CDs, and video games, completed a $6 million financing from Safeguard Scientifics, and also hired a new CEO. In March, the company pulled in $4.8 million of the round, which will go toward new hires and marketing.
—Lightower Fiber Networks, a Boxborough, MA-based owner and operator of 4,500 miles of data-transporting fiber that stretches from New England to Long Island, announced it is acquiring Westford, MA-based Veroxity Technology Partners, which runs about 2,000 miles of fiber in New England and New York City.
—T2 Biosystems, a Cambridge-based company that’s developing a portable diagnostic machine, raised $15 million in a deal led by Physic Ventures. Existing backers Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, and Partners Healthcare also participated in the financing, which brings the company’s total pot to about $31 million.
—Waltham’s Avila Therapeutics announced it will bring in as much as $209 million by partnering with Boulder, CO-based Clovis Oncology to develop drugs to fight certain types of lung tumors. The companies didn’t disclose how much of the money comes in the form of upfront payments versus milestones for the agreement, in which Clovis will fund development and commercialization of Avila’s lung cancer drugs, and will pay to develop a diagnostic test for identifying patients who are likely to benefit from the drug.